Revenue Breakdown
Composition ()
No data
Revenue Streams
Neuronetics Inc (STIM) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Clinic revenue, accounting for 60.4% of total sales, equivalent to $23.02M. Other significant revenue streams include Treatment sessions and NeuroStar Advanced Therapy System. Understanding this composition is critical for investors evaluating how STIM navigates market cycles within the Advanced Medical Equipment & Technology industry.
Profitability & Margins
Evaluating the bottom line, Neuronetics Inc maintains a gross margin of 45.87%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -19.63%, while the net margin is -25.21%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively STIM converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, STIM competes directly with industry leaders such as LNSR and EDAP. With a market capitalization of $151.35M, it holds a significant position in the sector. When comparing efficiency, STIM's gross margin of 45.87% stands against LNSR's 40.56% and EDAP's 43.02%. Such benchmarking helps identify whether Neuronetics Inc is trading at a premium or discount relative to its financial performance.
